{"symbol": "PKTX", "name": "ProtoKinetix", "next_earnings_utc": 1592301600, "next_earnings_period_start_date_utc": null, "next_earnings_period_end_date_utc": null, "next_earnings_has_time": true, "next_earnings_name": "None QNone", "next_earnings_year": null, "next_earnings_quarter": null, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": null, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": null, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 0, "analysts_sell": null, "analysts_buy": null, "analysts_outperform": null, "analysts_hold": null, "analysts_underperform": null, "webpage": "protokinetix.com", "year_founded": 1999, "street_address": "412 Mulberry Street", "city": "Marietta", "state": "OH", "zipcode": "45750", "country": "United States", "phone_number": "740 434 5041", "short_description": "ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in food and crop preservation at freezing temperatures.", "long_description": "ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in food and crop preservation at freezing temperatures. Its AAGPs have commercial applications in the harvesting, storage, and transplantation of cells, tissues, and organs; and treatments for conditions and diseases caused by stress factors, including UV radiation, oxidation, and inflammation. The company has collaboration agreement with the University of British Columbia to test neuronal retinal cells in living tissue for the treatment of macular degeneration; and research agreement with the University of Dalhousie to examine the effects of AAGP in transplant medicine. It develops AAGP to treat Dry Eye Disease therapy. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was founded in 1999 and is based in Marietta, Ohio.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "OTCQB", "equity_type": "stocks", "market_cap": 35937811, "total_enterprise": 35889922, "number_of_employees": 5, "outstanding_shares": 277622481, "eps": -0.025607, "diluted_eps": -0.025607, "earnings_from_cont_operations": -6984712, "gross_profit": null, "cash": 47889, "total_debt": 0, "total_revenue": null, "cash_from_operations": -1013429, "net_income": -6984712, "ebitda": -6981729, "year_low_stock_price": 0.08, "year_high_stock_price": 0.32, "seekingalpha_follower_count": 166, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/PKTX.png"}